Mersaco, in collaboration with Tabuk Pharmaceuticals, successfully hosted the launch event of Lurabil, a new-generation atypical antipsychotic, bringing together psychiatrists from across Lebanon for an engaging scientific meeting focused on the latest advancements in mental health care.

The event featured insightful presentations by distinguished experts Dr. Farid Talih, Dr. Rami Bou Khalil, and Dr. Abbas Alameddine, who shared their clinical expertise and discussed contemporary approaches to the management of psychiatric disorders. The meeting provided a valuable platform for scientific exchange, allowing attendees to explore emerging treatment strategies and their potential impact on patient outcomes.

Building on these scientific discussions, the launch of Lurabil represented more than the introduction of a new medication, it marked the availability of a new therapeutic option for psychiatrists in Lebanon. This milestone reflects the shared commitment of Mersaco and Tabuk Pharmaceuticals to advancing mental health care through innovation, evidence-based medicine, and continuous support for healthcare professionals in addressing the evolving needs of patients living with psychiatric conditions.

By combining scientific education with meaningful collaboration, the event underscored the vital role that knowledge sharing plays in improving standards of care and enhancing patient outcomes. Through initiatives such as this, Mersaco and Tabuk Pharmaceuticals continue to strengthen their partnership with the medical community, contributing to the advancement of mental health care and better quality of life for patients across Lebanon.